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Background: Epilepsy affects about 1% of the general population. Anti-epileptic drugs (AEDs) prevent or terminate
seizures in individuals with epilepsy. Pregnant women with epilepsy may continue taking AEDs. Many of these
agents cross the placenta and increase the risk of major congenital malformations, early cognitive and developmental
delays, and infant mortality. We aim to evaluate the comparative safety of AEDs approved for chronic use in
Canada when administered to pregnant and breastfeeding women and the effects on their infants and children
through a systematic review and network meta-analysis.
Methods: Studies examining the effects of AEDs administered to pregnant and breastfeeding women
regardless of indication (e.g., epilepsy, migraine, pain, psychiatric disorders) on their infants and children will
be included. We will include randomized clinical trials (RCTs), quasi-RCTs, non-RCTs, controlled before-after,
interrupted time series, cohort, registry, and case-control studies. The main literature search will be executed
in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. We will seek unpublished
literature through searches of trial protocol registries and conference abstracts. The literature search results
screening, data abstraction, and risk of bias appraisal will be performed by two individuals, independently.
Conflicts will be resolved through discussion. The risk of bias of experimental and quasi-experimental studies
will be appraised using the Cochrane Effective Practice and Organization of Care Risk-of-Bias tool, methodological
quality of observational studies will be appraised using the Newcastle-Ottawa Scale, and quality of reporting of safety
outcomes will be conducted using the McMaster Quality Assessment Scale of Harms (McHarm) tool. If feasible and
appropriate, we will conduct random effects meta-analysis. Network meta-analysis will be considered for outcomes that
fulfill network meta-analysis assumptions.
The primary outcome is major congenital malformations (overall and by specific types), while secondary outcomes
include fetal loss/miscarriage, minor congenital malformations (overall and by specific types), cognitive development,
psychomotor development, small for gestational age, preterm delivery, and neonatal seizures.
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Discussion: Our systematic review will address safety concerns regarding the use of AEDs during pregnancy and
breastfeeding. Our results will be useful to healthcare providers, policy-makers, and women of childbearing age who
are taking anti-epileptic medications.
Systematic review registration: PROSPERO CRD42014008925.
Keywords: Anti-epileptic drug, Breastfeeding, Comparative safety, Congenital malformation, Epilepsy, Fetus, Infant,
Network meta-analysis, Pregnancy, Systematic reviewBackground
Epilepsy is the most common chronic neurological con-
dition, affecting 0.6 to 1% of the population [1,2]. Indi-
viduals with uncontrolled epilepsy experience recurrent
seizures, which can have psychosocial and physical con-
sequences, including a compromised life expectancy [3,4].
The goal of anti-epileptic treatment is to improve quality
of life and health outcomes by reducing the frequency
of seizures [4].
Anti-epileptic medications decrease seizures by reducing
excitation and enhancing inhibition of neurons [5-7]. Many
of these medications target different channels, including
calcium, sodium, and glutamate, and are broadly classified
as first generation agents (e.g., phenobarbitone, phenytoin,
carbamazepine, sodium valproate, ethosuximide) and
second generation agents (e.g., lamotrigine, levetiracetam,
topiramate, gabapentin, vigabatrin, oxcarbazepine, cloba-
zam, clonazepam, zonisamide, lacosamide, rufinamide, pri-
midone) [8]. Due to the broad and varied mechanisms of
action, the indications for some of these medications also
include pain syndromes, psychiatric disorders, and migraine
headaches [8].
Many clinical practice guidelines recommend that women
of childbearing age continue to take their anti-epileptic med-
ications; however, medications with lower risk of teratogenic
events are advised [9,10] since anti-epileptic drugs (AEDs)
cross the placenta or transfer through breast milk, posing
risks to the fetus and infant [9,11,12].
Some AEDs have been associated with increased risk
of harm to the fetus and infants. For example, exposure
to valproate has led to increased risk of major congenital
malformations [10], cognitive delay, and minor congenital
abnormalities [13-16]. Phenobarbital has been associated
with minor congenital abnormalities and developmental
delay [17,18]. Carbamazepine and lamotrigine have been
associated with minor congenital abnormalities [19-22].
However, other than studies of the use of valproate, many
studies have produced inconsistent findings regarding
harm to the fetus and infant with use of other agents [23].
As such, our objective is to evaluate the comparative
safety of AEDs for infants and children who were exposed
in utero or during breastfeeding through a systematic
review and network meta-analysis.Methods/Design
Protocol
A systematic review protocol was developed and registered
with the PROSPERO database (CRD42014008925, available
at: http://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42014008925). It was revised with feedback
from the decision-makers who posed the query within
Health Canada, healthcare practitioners, content experts,
and research methodologists. The reporting of our sys-
tematic review protocol was guided by the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
Protocols [24].
Eligibility criteria
We will include studies examining the effects of AEDs
on infants and children who were exposed in utero or
during breastfeeding. We will include experimental stu-
dies (randomized clinical trials [RCTs], quasi-RCTs,
non-RCTs), quasi-experimental studies (controlled be-
fore and after studies, interrupted time series), and ob-
servational studies (cohort, case-control, registry studies)
of pregnant women at any stage of pregnancy and
breastfeeding women and their infants/children. The ra-
tionale for including other study designs in addition to
RCTs is that there are ethical issues in conducting RCTs
of AEDs in pregnancy, so RCT evidence might not exist
for some or all of these drugs. Given that our review in-
cludes rare outcomes, including observational evidence
is crucial. In contrast to efficacy evaluation, safety assess-
ment usually requires very large sample sizes to be able to
detect adverse events. Therefore, while RCTs have lower
risk of bias, they usually do not have the statistical power
needed to adequately evaluate uncommon/rare safety out-
comes due to Type II (i.e., false negative) error [25]. Given
that our review includes rare outcomes, including obser-
vational evidence is crucial [26]. Additionally, observa-
tional studies can often provide more generalizable
evidence due to the strict participant inclusion criteria in
most RCTs [27]. Real-world safety evidence that has exter-
nal validity is important for the assessment of the possible
risks of AEDs in pregnant and breastfeeding women.
The diagnosis of neurodevelopmental delay related to
in utero exposure is made before adolescence, and
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of age. AEDs that are approved for chronic use in Canada
will be included. Drugs that are only used acutely or those
that are not currently approved for use in Canada will be
excluded, as the focus of this review is on the Canadian
setting [28-32]. However, most of the medications we
will examine are available in other countries as well.
The relevant 16 medications and their synonyms are
listed in Additional file 1, and the excluded drugs are
listed in Additional file 2. Studies of all combinations
and doses of these medications are eligible for inclusion.
Since we are only interested in exposures that occur in
utero or during breastfeeding, studies examining AEDs
administered directly to infants or children will be
excluded. All indications for AEDs will be included such
as epilepsy, migraine, pain, and psychiatric disorders.
In order to be included, studies must compare an anti-
epileptic medication against another included anti-epileptic
medication, placebo, a ‘no intervention’ control group, or
combinations of two or more anti-epileptic medications.
Only studies providing results for our outcomes of interest
will be included. Our primary outcome is major congeni-
tal malformations (overall and by specific type, such as
craniofacial defects and neural tube defects). Secondary
outcomes include minor congenital malformations (over-
all and by specific type, such as epicanthal folds and
microstomia), cognition (e.g., global cognitive functioning
and specific cognitive domains such as attention), psycho-
motor development (e.g., autism, dyspraxia), small for ges-
tational age, preterm delivery, neonatal seizures, and fetal
loss/miscarriage. No other limitations will be imposed on
the eligibility criteria, including published/unpublished
material, language of dissemination, duration of follow-up,
or year of publication. The draft eligibility criteria can be
found in Additional file 3.Information sources and literature search
Our main literature search will be executed in the MED-
LINE database. The search terms were drafted by an expe-
rienced librarian and can be found in Additional file 4. The
search was peer reviewed by another librarian using the
Peer Review of Electronic Search Strategies checklist [33].
In addition to MEDLINE, we will also search the
EMBASE and the Cochrane Central Register of Con-
trolled Trials databases. We will follow the MEDLINE
search strategy for these databases, and the search
terms will be adjusted accordingly. The electronic
database search will be supplemented by searching for
unpublished literature [34]. This will be accomplished
through exploring conference abstracts, clinical trial
registries, and contacting manufacturers of AEDs. We
will also scan the reference lists of included studies
and previous reviews in the area [23,35,36].Study selection process
The eligibility criteria screening form will be pilot-tested
by the team and is presented in Additional file 3. We
will calculate inter-rater reliability from the pilot-test
and screening will only commence after high agreement
(e.g., kappa statistic ≥60%) is observed [37]. Subsequently,
two reviewers will screen each title/abstract and poten-
tially relevant full-text articles from the literature search
results, independently. Conflicts will be resolved through
discussion. All screening will occur using our online
screening software (synthesi.SR) [38].
Data items and data collection process
We will abstract data on the PICOS elements [39], in-
cluding patient characteristics (e.g., age of the mother
and infant/child, indication for anti-epileptic treatment,
co-morbidities, concomitant medications), intervention
details (e.g., type of anti-epileptic treatment, dose, route
of administration, duration of treatment, timing [trimes-
ter] of treatment during pregnancy), comparator details
(e.g., comparator agent, dose, route of administration),
outcome results (e.g., major congenital abnormality, minor
congenital abnormality, cognitive function, psychomotor
development) at the longest duration of follow-up, and
study characteristics (e.g., study design, country of con-
duct, year of conduct, sample size, setting). These charac-
teristics will be abstracted using a data abstraction form
created in Excel with an accompanying “cheat sheet” that
will guide the reviewers with this process. The data ab-
straction form and cheat sheet will be pilot-tested and
data abstraction will only commence when high agree-
ment (e.g., kappa statistic ≥60%) [37] is observed. Each
included study will be abstracted by two team members,
independently, who will resolve disagreements through
discussion.
Methodological quality/risk of bias appraisal
We will use various tools to assess the methodological
quality/risk of bias of each of the studies that fulfill our
eligibility criteria. This will be conducted by two reviewers,
independently, and conflicts will be resolved through dis-
cussion. First, we will appraise the risk of bias of experi-
mental and quasi-experimental studies using the Cochrane
Effective Practice and Organization of Care Risk-of-Bias
tool [40]. Second, we will assess the methodological quality
of observational studies using the Newcastle-Ottawa Scale
[41]. Third, the quality of reporting of harms will be
appraised using the McMaster Quality Assessment Scale
of Harms (McHarm) tool [42].
Synthesis of included studies
A narrative summary of study results will be presented
along with evidence summary tables. When sufficient
data are available, we will conduct random effects meta-
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data and pooled mean differences for continuous data
[43,44]. Direct (pairwise) meta-analysis will be per-
formed with RCTs alone in order to examine whether
the data are consistent between direct and indirect evi-
dence. If the large majority of included studies are obser-
vational, we will also conduct additional meta-analyses
including observational studies alone. Analyses will be
stratified by treatment indication (e.g., epilepsy, pain,
etc.) to reduce clinical heterogeneity between different
study populations whenever possible; for example, epi-
lepsy itself in pregnant women is related to an increased
baseline risk of certain neonatal adverse outcomes. Stat-
istical, clinical, and methodological heterogeneity will be
examined prior to conducting the meta-analysis. Funnel
plots will be drawn for outcomes including at least 10
studies to explore asymmetry that might be explained by
clinical, statistical, and methodological heterogeneity.
The proportion of statistical heterogeneity will be exam-
ined using the I2 measure [45] and the magnitude of
statistical heterogeneity will be calculated using the re-
stricted maximum likelihood [46]. Meta-regression will
be conducted for clinically relevant subgroups or when
extensive statistical heterogeneity is observed (e.g., I2 ≥
75%) [47]. This will allow the examination of the impact
of important factors on our results, such as maternal
age, dose, duration and timing (e.g., trimester) of anti-
epileptic treatment, co-morbidities, concomitant medi-
cations, risk of bias results, and sample size (due to Type
II statistical power errors with rare adverse events). To
ensure the meta-regression analysis is intuitive, the num-
ber of covariates examined will be less than 10% of the
number of studies included in the meta-analysis for the
particular outcome.
We anticipate that many of these outcomes will be
rare. To deal with studies reporting zero events in one
treatment arm, 0.5 will be added to the numerator and 1
will be added to the denominator. We will exclude stud-
ies reporting zero events in all treatment arms for a par-
ticular outcome [48,49]. We also anticipate that we will
encounter missing data in the included studies. We will
contact the study authors for this data and if we are
unable to receive the data, we will impute missing data
(e.g., measures of variance) using established methods
[50]. To ensure that our imputations do not bias our
results, we will conduct a sensitivity analysis [51]. The
meta-analysis and meta-regression will be analyzed in R
using the metafor command [52].
A random-effects network meta-analysis will be con-
ducted to make inferences regarding the comparative
safety of the various AEDs [15], as well as rank their safety
using rankograms and the surface under the cumulative
ranking curve [53]. We will ensure the following factors
are present prior to conducting network meta-analysis:i) transitivity (i.e., comparable distribution of effect
modifiers across comparisons), which will be examined
using boxplots or percentages to visually inspect potential
effect modifiers of treatment effect [54]; ii) consistency
between direct and indirect data, which will be exam-
ined locally (i.e., in certain paths of the network) using
the loop-specific method [55,56] and the node-splitting
method [57], and globally (i.e., evaluating the network
as a whole), using the design-by-treatment interaction
model [58]; and iii) we will quantify the amount of vari-
ability attributed to heterogeneity and inconsistency ra-
ther than sampling error, by calculating the I2 [59]. We
will estimate the amount of heterogeneity using the re-
stricted maximum likelihood method and assuming
common within-network heterogeneity. We will compare
the magnitude of heterogeneity between consistency and
inconsistency models, as well as between meta-regression
and network meta-analysis models to determine how
much heterogeneity will be explained by inconsistency or
the explanatory variable, respectively. We will first use the
design-by-treatment model for the evaluation of incon-
sistency in a network as a whole and then, if inconsist-
ency is detected, we will employ the loop-specific and
node-splitting methods to identify which piece of evi-
dence is responsible for inconsistency. As mentioned
above, analyses will be stratified by treatment indication
when clinically appropriate. Important heterogeneity
and inconsistency will be explored using network meta-
regression using the same methods as described above,
as necessary.
Prior to conducting the network meta-analysis, we will
hold a team meeting to finalize which treatment nodes
will be included in the analysis since we are unclear
about the indications, dosages, patient populations, and
outcomes reported in all of the studies. We will discuss
issues, including conducting a class versus independent
drug analysis, inclusion of drug routes of administration
and dosages, as well as timing of drug administration.
These decisions will be examined through a sensitivity
analysis in which we will classify treatment nodes using
a different classification to see how stable our results
are. The network meta-analysis results will be presented
as summary treatment effects for each pair of treat-
ments. Network meta-analysis will be conducted in Stata
with the mvmeta routine [60].
A sequential approach will be used for the network
meta-analysis. We will first restrict our analysis to RCTs,
which will be the primary analysis of interest. We will
then include data from quasi-experimental studies, and
finally, data from observational studies. This will provide
an understanding of the contribution of each type of
study design to our summary estimates, providing us
with information on how these agents work above and
beyond clinical trials.
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Epilepsy is the most common chronic neurological con-
dition, affecting 0.6 to 1% of the population [1,2]. Given
that approximately a third of patients receiving AEDs
are of reproductive age and almost half of pregnancies
are unplanned [61], the fetus may be exposed to these in
the first trimester of pregnancy, including during the
critical stage of embryogenesis [62].
The comparative safety of these agents is currently un-
known and our results will be important for policy-
makers, healthcare providers, and women of childbearing
age. To ensure our results have wide dissemination and
uptake, we will publish our results in open access journals,
present our findings at scientific conferences, conduct
dissemination meetings with key stakeholders (including
policy-makers and healthcare providers), and produce
policy briefs for Health Canada, the organization that
posed this query.
Additional files
Additional file 1: List of relevant medications.
Additional file 2: Excluded drugs.
Additional file 3: Draft eligibility criteria.
Additional file 4: MEDLINE literature search.
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